This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more
The Boston criteria version 2.0 for cerebral amyloid angiopathy This is for informational purposes only
The Boston criteria version 2.0 (v2.0) study improves cerebral amyloid angiopathy (CAA) diagnosis by incorporating non-hemorrhagic MRI markers like centrum semiovale perivascular spaces (CSO-PVS) and white matter hyperintensities, increasing sensitivity to 74.5%. This multicentre, retrospective study validated these updated criteria against neuropathology across diverse clinical scenarios, including cognitive impairment and transient focal neurological episodes. Access the full-text article at PMC . increasing sensitivity to 74.5%. This multicentre